Regencell Bioscience Class Action Lawsuit
Analysis based on 7 articles · First reported Apr 27, 2026 · Last updated Jun 03, 2026
The class action lawsuit against Regencell Bioscience Holdings is likely to negatively impact its stock price and investor confidence due to allegations of securities fraud and market manipulation. For Bronstein, Gewirtz & Grossman, LLC, this action could enhance its reputation as an investor-rights law firm.
A class action lawsuit has been filed against Regencell Bioscience Holdings and its officers by Bronstein, Gewirtz & Grossman, LLC. The lawsuit alleges that Regencell Bioscience Holdings made materially false and misleading statements regarding its business, operations, and compliance policies between October 28, 2024, and October 31, 2025. Specifically, the complaint claims that Regencell Bioscience Holdings was vulnerable to market manipulation, which exposed investors to significant financial risk, and that this subjected the company to a heightened risk of regulatory scrutiny and harm. Investors who suffered losses are encouraged to join the case, with a deadline of June 23, 2026, to request to be appointed as lead plaintiff. Peretz Bronstein and Nathan Miller are key contacts for the law firm.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard